Levofloxacin for Bacterial Otitis Media

Efficacy of Levofloxacin in Otitis Media

Levofloxacin has demonstrated excellent bacterial eradication rates (88%) in children with recurrent or persistent otitis media, including 84% eradication of S. pneumoniae and 100% eradication of H. influenzae 1
Levofloxacin has been shown to have enhanced activity against the common pathogens in otitis media, including Streptococcus pneumoniae (including drug-resistant strains) and Haemophilus influenzae 2, 1

The American Academy of Pediatrics recommends limiting fluoroquinolone use to appropriate indications to prevent development of antimicrobial resistance 2, 3
Levofloxacin should not be used as first-line therapy for simple acute bacterial otitis media 2, 3
Levofloxacin should be reserved for cases where first-line treatments have failed 4
The French guidelines recommend levofloxacin as a second-line antibiotic for treatment failures or frequent exacerbations, not as first-line therapy 4, 5

Levofloxacin has enhanced activity against Moraxella catarrhalis 1
Levofloxacin is particularly effective against fluoroquinolone-susceptible strains 2, 1

For children under 2 years with AOM, antibiotic therapy is recommended (Grade A evidence), but fluoroquinolones are not first-line 4
The pharmaceutical manufacturer has not sought FDA approval for levofloxacin use in acute bacterial otitis media in children 2, 3

For resistant otitis media in children, levofloxacin should be dosed at 10 mg/kg twice daily for 10 days, as recommended by the American Academy of Pediatrics, but this should only be used as second-line therapy after first-line agents have failed 6
Children under 5 years should receive 10 mg/kg divided twice daily, with a maximum of 750 mg per dose, as per the dosing guidelines 6
The American Academy of Pediatrics recommends that children 5 years and older receive 10 mg/kg once daily, with a maximum of 750 mg per dose 6

High-dose amoxicillin-clavulanate (90 mg/6.4 mg per kg per day) should be attempted first, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery, before considering levofloxacin as second-line therapy 7

The American Academy of Pediatrics recommends monitoring for musculoskeletal adverse effects, though these are rare in short courses, when using levofloxacin 6

The American Academy of Otolaryngology-Head and Neck Surgery recommends ceftriaxone (parenteral) as an alternative second-line option, at a dose of 50 mg/kg IM/IV daily for 3 days, if levofloxacin is contraindicated or unavailable 7